Leukemia
MONDO:0005059A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.
Also known as: blood (leukemia), leukaemia (disease), leukemia, leukemia (disease), leukemia, disease, leukemia, malignant, leukemias, leukemias, general
4316 clinical trials for this condition and its sub-types, 360 tagged with Leukemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Leukemia
-
Acute leukemia 123 trials · 2,241 incl. sub-types
4 sub-types
- Acute lymphoblastic leukemia 507 trials · 1,317 incl. sub-types Sub-types →
- Acute myeloid leukemia 1,097 trials · 1,192 incl. sub-types Sub-types →
- Leukemia, acute, X-linked 0 trials
- Subacute leukemia 0 trials
-
Lymphoid leukemia 23 trials · 1,360 incl. sub-types
3 sub-types
- Acute lymphoblastic leukemia 507 trials · 1,317 incl. sub-types Sub-types →
- T-cell leukemia 9 trials · 137 incl. sub-types Sub-types →
- T-cell large granular lymphocyte leukemia 18 trials
-
Myeloid leukemia 30 trials · 1,332 incl. sub-types
4 sub-types
- Acute myeloid leukemia 1,097 trials · 1,192 incl. sub-types Sub-types →
- Chronic myelogenous leukemia, BCR-ABL1 positive 211 trials · 253 incl. sub-types Sub-types →
- Atypical chronic myeloid leukemia, BCR-ABL1 negative 17 trials
- Philadelphia-positive myelogenous leukemia 2 trials
-
Chronic leukemia 15 trials · 747 incl. sub-types
8 sub-types
- B-cell chronic lymphocytic leukemia 509 trials · 538 incl. sub-types Sub-types →
- Chronic myelomonocytic leukemia 166 trials · 186 incl. sub-types Sub-types →
- Prolymphocytic leukemia 20 trials · 38 incl. sub-types Sub-types →
- T-cell large granular lymphocyte leukemia 18 trials
- Aggressive NK-cell leukemia 11 trials
- Chronic neutrophilic leukemia 10 trials
- Chronic eosinophilic leukemia 9 trials
- Chronic monocytic leukemia 2 trials
-
Childhood leukemia 23 trials · 172 incl. sub-types
3 sub-types
- Childhood acute lymphoblastic leukemia 96 trials · 136 incl. sub-types Sub-types →
- Childhood acute myeloid leukemia 24 trials
- Neonatal leukemia 0 trials
-
Monocytic leukemia 4 trials · 22 incl. sub-types
2 sub-types
- Acute monocytic leukemia 20 trials Sub-types →
- Chronic monocytic leukemia 2 trials
-
Mast cell leukemia 9 trials
-
Central nervous system leukemia 4 trials
-
Testicular leukemia 2 trials
-
Aleukemic leukemia 0 trials
1 sub-type
- Aleukemic leukemia cutis 0 trials Sub-types →
-
Chronic erythremia 0 trials
-
Splenic manifestation of leukemia 0 trials
2 sub-types
Most studied deeper sub-types
-
Engineered immune cells take aim at Hard-to-Treat leukemias
Cure CompletedThis trial is testing a new type of immune cell therapy called CD123 CAR-NK cells in people with relapsed or refractory acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN). The cells are designed to find and attack cancer cells that carry a protei…
Phase 1/2 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Cure
Last updated Aug 07, 2026 00:00 UTC
-
Two-Drug combo aims to push CLL into deep remission
Disease control CompletedResearchers are testing whether combining ibrutinib and venetoclax can help people with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The trial assigns participants to either a fixed course of the two drugs or a course guided by a sensitive test…
Phase 2 • Sponsor: Pharmacyclics LLC. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Old drug, new hope: enasidenib may ease anemia in blood cancer patients
Disease control CompletedThis early-phase trial tested the drug enasidenib in 17 people with low-risk myelodysplastic syndrome or a related leukemia who had anemia and did not have a specific gene mutation. The goal was to see if the drug could safely improve red blood cell counts and reduce the need for…
Phase 1/2 • Sponsor: Tian Yi Zhang • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Experimental drug shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis study tests a drug called CPI-613 in people with relapsed or hard-to-treat Burkitt lymphoma or high-grade B-cell lymphoma. About 24 participants aged 12 and older who have not responded to at least one prior treatment will receive the drug. The goal is to see if the drug can…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Leukemia drug holiday: study finds many can stop imatinib without relapse
Disease control CompletedThis study looked at 220 adults with chronic myeloid leukemia who had been in deep remission for at least two years while taking imatinib. Researchers wanted to see if stopping the drug would cause the cancer to come back. They found that many patients stayed in remission after s…
Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Major study finds safer way to give key leukemia drug to kids
Disease control CompletedThis study looked at 800 children with acute lymphoblastic leukemia to compare two forms of the drug asparaginase: a pegylated version given through a vein and a standard version given as a shot. The goal was to see which caused fewer serious side effects like allergic reactions,…
Phase 3 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a targeted antibody boost chemotherapy against a rare leukemia?
Disease control CompletedThis study tests whether adding a targeted drug called brentuximab vedotin to standard chemotherapy can help people with adult T-cell leukemia/lymphoma (ATLL), a rare and aggressive blood cancer. The combination, known as BV-CHEP, aims to improve response rates by targeting a mar…
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New targeted drug shows promise for Hard-to-Treat leukemia
Disease control CompletedThis study tested a drug called acalabrutinib in 48 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had a specific high-risk genetic change (deletion 17p). Some participants had already tried other treatments, while others were newly diagnos…
Phase 2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Experimental drug RAD001 tested for tough leukemias and lymphomas
Disease control CompletedThis study tested the drug RAD001 (everolimus) in 29 patients with relapsed or hard-to-treat blood cancers like leukemia, lymphoma, and myelofibrosis. The goal was to find the safest highest dose and see if it helps control the disease. It was a small early-phase trial at a singl…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells target tough leukemia in early trial
Disease control CompletedThis early-phase study tested a new treatment for children and young adults with a type of leukemia that came back or did not respond to standard therapy. The approach uses the patient's own immune cells, modified in a lab to recognize and attack cancer cells carrying a protein c…
Phase 1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug combo shrinks spleens in bone marrow cancer patients
Disease control CompletedThis study tested a new drug called pelabresib in people with certain blood cancers, including myelofibrosis and leukemia. In the first part, the drug was given alone to find the safest dose. In the second part, it was given with or without another drug (ruxolitinib) to see if it…
Phase 1/2 • Sponsor: Constellation Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Intense Pre-Transplant combo shows promise for tough leukemias
Disease control CompletedThis phase 2 trial tested a combination of intravenous busulfan, etoposide, and low-dose total-body irradiation before a donor stem cell or bone marrow transplant in 30 patients with advanced leukemia or myelodysplastic syndromes. The goal was to see how well this regimen control…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo may make cord blood transplants safer for blood cancer patients
Disease control CompletedThis study tested whether adding the drug tocilizumab to standard care could reduce the risk of graft-versus-host disease (GVHD) after a cord blood transplant in adults with blood cancers. GVHD is a serious complication where donor cells attack the patient's body. Tocilizumab blo…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Early trial checks safety of blinatumomab in japanese leukemia patients
Disease control CompletedThis early-phase study tested the safety of the drug blinatumomab (Blincyto®) in 6 Japanese adults newly diagnosed with a type of leukemia called B-ALL. The main goal was to see what side effects occurred. Researchers also looked at how the drug moves through the body and whether…
Phase 1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for young leukemia patients: combination chemo shows promise
Disease control CompletedThis study tested a combination of chemotherapy drugs in 318 adolescents and young adults (ages not specified but typically 15-39) with newly diagnosed acute lymphoblastic leukemia (ALL). The goal was to see how well the treatment worked at killing cancer cells and stopping the d…
Phase 2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New combo pill shows promise for stubborn leukemia
Disease control CompletedThis phase 2 trial tested whether adding asciminib to the standard drug imatinib helps people with chronic myeloid leukemia (CML) achieve deeper remission. 104 adults who had been on imatinib for at least a year without reaching very low cancer levels were randomly assigned to ad…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Engineered immune cells take on tough blood cancers in early trial
Disease control CompletedThis study tested a new treatment called CTX131 for adults with certain blood cancers (T-cell lymphoma, B-cell lymphoma, or acute myeloid leukemia) that had returned or stopped responding to standard therapy. CTX131 uses a patient's own immune cells, modified with CRISPR gene edi…
Phase 1/2 • Sponsor: CRISPR Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New radiation combo aims to boost stem cell transplant success in tough leukemia cases
Disease control CompletedThis study tested a new way to prepare patients with relapsed or hard-to-treat acute leukemia for a donor stem cell transplant. It combined a precise form of radiation therapy (IMRT) with two chemotherapy drugs (etoposide and cyclophosphamide) before the transplant. The goal was …
Phase 1/2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New Two-Step transplant shows promise for tough blood cancers
Disease control CompletedThis phase 2 trial tested a two-step stem cell transplant approach for 47 patients with high-risk blood cancers like leukemia and lymphoma. The method uses the drug cyclophosphamide to lower the chance of graft-versus-host disease (GVHD), a common complication. The goal was to se…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New dosing study aims to tame Drug-Resistant leukemia
Disease control CompletedThis study tested three different starting doses (45 mg, 30 mg, and 15 mg daily) of the drug ponatinib in 283 adults with chronic phase chronic myeloid leukemia (CML) that had stopped responding to other treatments or had a specific genetic mutation (T315I). The main goal was to …
Phase 2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New combo therapy shows promise for tough childhood leukemia
Disease control CompletedThis study tested whether adding the targeted drug ruxolitinib to standard chemotherapy helps children with a high-risk form of acute lymphoblastic leukemia (ALL). The trial involved 171 children and young adults aged 1 to 21. Researchers first found the best dose of ruxolitinib,…
Phase 2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
One donor, two transplants: could this end lifelong Anti-Rejection drugs?
Disease control CompletedThis pilot study tested a combined bone marrow and kidney transplant from a partially matched family donor in 10 people with both a blood disorder and chronic kidney disease. The goal was to treat both conditions at once and possibly reduce the need for lifelong anti-rejection dr…
Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New combo therapy shows promise for First-Line CLL treatment
Disease control CompletedThis phase 2 trial tested a combination of bendamustine and rituximab (BR) followed by venetoclax in 42 people with untreated chronic lymphocytic leukemia (CLL). The goal was to see how many patients responded to the full 15-month treatment. Venetoclax is an oral drug that target…
Phase 2 • Sponsor: Nicole Lamanna • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New combo therapy shows promise for aggressive leukemia
Disease control CompletedThis study tested a drug called dasatinib combined with standard chemotherapy in 30 adults newly diagnosed with a fast-growing leukemia (Ph+ ALL). The goal was to see if the combination helps people live longer and keeps the cancer away. Patients took dasatinib daily for up to 2 …
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Can a targeted drug tame CLL? small trial seeks answers
Disease control CompletedThis Phase 2 trial tested the drug dasatinib in 17 people with chronic lymphocytic leukemia (CLL) who had already received other treatments. The goal was to see if dasatinib could shrink or control the cancer. Participants took the drug by mouth twice daily, and doctors checked f…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Drug dasatinib tested for rare blood cancers
Disease control CompletedThis study tested the drug dasatinib in 68 adults with several types of blood and bone marrow disorders, including certain leukemias, myelofibrosis, and mastocytosis. The goal was to see if dasatinib could help control the disease and to check its safety. Participants took dasati…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New cocktail aims to knock out leukemia for good
Disease control CompletedThis phase 2 study tested a combination of three drugs—ofatumumab, high-dose methylprednisolone, and lenalidomide—in 45 people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal was to see if this approach could make all signs of cance…
Phase 2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
High-Dose therapy plus stem cell transplant shows promise for AML patients
Disease control CompletedThis phase 2 trial tested a treatment for adults with acute myeloid leukemia (AML) in first remission. Patients received high-dose chemotherapy and radiation to kill cancer cells, followed by an autologous stem cell transplant (using their own stem cells) to restore blood cell pr…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New chemo combo before donor transplant shows promise for leukemia patients
Disease control CompletedThis study tested adding a drug called thiotepa to the usual chemotherapy given before a donor stem cell transplant for people with leukemia. The goal was to see if this stronger mix could help more patients stay cancer-free one year after the transplant. The study included 40 ad…
Phase 2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Experimental drug shows promise for Hard-to-Treat lymphoma
Disease control CompletedThis study tested a drug called brentuximab vedotin in 23 people with a type of T-cell lymphoma that had stopped responding to or returned after prior chemotherapy. The drug is designed to seek out and kill cancer cells that have a specific marker called CD30, even when levels of…
Phase 2 • Sponsor: Deepa Jagadeesh • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New drug combo may make bone marrow transplants safer for blood cancer patients
Disease control CompletedThis early-phase trial tested replacing the standard drug cyclophosphamide with bendamustine after a half-matched bone marrow transplant in 50 patients with various blood cancers. The goal was to see if this change could reduce side effects like graft-versus-host disease while st…
Phase 1 • Sponsor: University of Arizona • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
App helps young cancer survivors shed pounds
Disease control CompletedThis study tested a smartphone app to help young adult cancer survivors (ages 18-39) lose weight. The app tracked diet and activity as part of a behavioral weight loss program. The goal was to see if this approach was practical and well-liked by participants. The study involved 6…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New hope for kids with tough cancers: experimental combo shows promise
Disease control CompletedThis early-phase study tested a three-drug combination (carfilzomib, cyclophosphamide, and etoposide) in 4 children whose solid tumors or leukemias had come back or didn't respond to standard treatment. The main goal was to find the safest dose and identify side effects. The stud…
Phase 1 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New hope for young AML patients: epigenetic drugs plus chemotherapy show promise
Disease control CompletedThis early-phase study tested whether adding two drugs (decitabine and vorinostat) before and during standard chemotherapy (FLAG) is safe for children and young adults up to age 25 with acute myeloid leukemia (AML) that has come back or not responded to treatment. The goal was to…
Phase 1 • Sponsor: Therapeutic Advances in Childhood Leukemia Consortium • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New pill combo extends life for leukemia patients too frail for strong chemo
Disease control CompletedThis study tested whether adding the drug venetoclax to a low-dose chemotherapy (LDAC) helps people with acute myeloid leukemia (AML) live longer. It included 211 adults aged 75+ or 18–74 with health issues that prevent them from receiving strong chemotherapy. The main goal was t…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug may reduce transplant complications in blood cancer patients
Disease control CompletedThis study tested whether the drug palifermin could make stem cell transplants safer and reduce chronic graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. Thirty-four adults with blood cancers received palifermin before transplan…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New immune therapy shows promise in early leukemia trial
Disease control CompletedThis early-phase study tested a new treatment called WU-NK-101 in 9 adults with acute myeloid leukemia (AML) that returned or didn't respond to standard therapy. The goal was to check safety and find the best dose. Participants received immune cells designed to attack cancer. Thi…
Phase 1 • Sponsor: Wugen, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New ultrasound could spot heart trouble before It's too late for chemo patients
Diagnosis CompletedThis study tested whether a special heart ultrasound (2D strain imaging) can detect early signs of heart damage caused by anthracycline chemotherapy in 100 leukemia patients. The goal is to catch problems sooner, so doctors can adjust treatment and reduce the risk of permanent he…
Sponsor: University Hospital, Bordeaux • Aim: Diagnosis
Last updated Jun 27, 2026 12:39 UTC
-
New DNA test could speed up fungal infection diagnosis in cancer patients
Diagnosis CompletedThis study tested a new DNA test called the MycoGenie kit to see how well it can diagnose invasive aspergillosis, a serious fungal infection, in 350 blood cancer patients. The test looks for the fungus's DNA in blood samples and can also detect drug resistance. The goal is to fin…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Diagnosis
Last updated Jun 27, 2026 07:58 UTC
-
Gentle touch may soothe anxiety for isolated blood cancer patients
Symptom relief CompletedThis study looked at whether touch-massage can reduce anxiety in people with blood disorders (like leukemia or lymphoma) who are hospitalized in a sterile, isolated room. Sixty-two patients received three massage sessions, and researchers measured their anxiety levels before and …
Sponsor: Nantes University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Fencing fights fatigue: new program aims to keep blood cancer patients moving
Symptom relief CompletedThis study tested whether a fencing-based exercise program is practical for adults with leukemia or lymphoma who are receiving intensive treatment in a hospital. The goal was to reduce physical decline caused by long bed rest. Eighty patients were invited to take part, and resear…
Sponsor: University Hospital, Angers • Aim: Symptom relief
Last updated Jun 27, 2026 12:39 UTC
-
Can extra support ease the burden of AML? new study says yes.
Symptom relief CompletedThis study tested whether adding a palliative care team to standard cancer care improves quality of life for people with acute myeloid leukemia (AML). 160 hospitalized patients with high-risk AML were randomly assigned to receive either usual oncology care or care that included a…
Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC
-
Free blood transfusions help blood cancer patients choose hospice
Symptom relief CompletedThis study looked at whether providing free blood transfusions to blood cancer patients would encourage them to enroll in hospice care earlier. Many patients delay hospice because they need transfusions for symptom relief, but hospices often cannot afford to provide them. The stu…
Sponsor: Adam Olszewski • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
Teens who beat cancer get stronger with simple strength exercises
Symptom relief CompletedThis study looked at whether 16 weeks of strength training can reduce long-term side effects in teens aged 10-19 who finished treatment for leukemia or lymphoma. Participants did either strength exercises with weights or circuit training with bodyweight and equipment. The goal wa…
Sponsor: Aalborg University • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Monthly chat group may ease isolation for young transplant patients
Symptom relief CompletedThis study tested a monthly online peer support group for young adults (ages 18-39) who had received a stem cell transplant. The group met for one hour over six months, led by a nurse and social worker. The goal was to see if the program was practical and helpful for reducing anx…
Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC
-
New online program eases Kids' cancer return to school
Symptom relief CompletedThis study tested a web-based program to help children aged 8-17 with cancer adjust to returning to school. The program included modules for children, parents, teachers, and peers, focusing on communication, coping, and social skills. Twenty children participated, and researchers…
Sponsor: Gazi University • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
Empowerment program shows promise for healthier habits in young leukemia patients
Symptom relief CompletedThis study tested a child-centered empowerment program designed to help children with leukemia improve their lifestyle habits, including nutrition, sleep, physical activity, and stress management. Forty-six children aged 7-13 took part, with half receiving the program and half ge…
Sponsor: Near East University, Turkey • Aim: Symptom relief
Last updated Jun 26, 2026 14:44 UTC
-
Dust and crops: scientists hunt for Pesticide-Leukemia link in kids
Knowledge-focused CompletedThis study looked at 629 children in California to see if exposure to pesticides at home or from nearby farms is linked to childhood leukemia. Researchers collected dust from carpets and vacuum cleaners and mapped crops near homes. The goal was to measure chemical levels and see …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists decode cancer genes to personalize treatment
Knowledge-focused CompletedThis completed study analyzed genetic material from 1,340 patients with lymphoma, leukemia, or multiple myeloma. Researchers used DNA microarrays and other tools to find new molecular subtypes that could explain why some patients respond better to treatment than others. The goal …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Farmers' pesticide use linked to blood cancer precursors
Knowledge-focused CompletedThis study looked at nearly 1,900 male farmers over age 50 to see if pesticide exposure is linked to early signs of blood cancers like multiple myeloma. Researchers collected blood and urine samples and compared those with and without exposure to the pesticide diazinon. No treatm…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Can a phone call help cancer survivors get the genetic answers they need?
Knowledge-focused CompletedThis study looked at whether offering genetic counseling by phone or video could help more childhood cancer survivors get genetic testing. About 391 survivors took part, comparing remote counseling to usual care. The goal was to see if remote services increase testing uptake and …
Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
New dashboard aims to make leukemia trials more inclusive
Knowledge-focused CompletedThis study tests a data visualization tool called the Trial Enrollment Diversity Dashboard (TEDD) designed to help doctors see how diverse their clinical trial enrollments are. The goal is to overcome racial and ethnic disparities in leukemia trial participation. The study enroll…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Could natural immune cells help fight leukemia drug resistance?
Knowledge-focused CompletedThis completed study from France examined whether a specific type of immune cell (innate CD8+ T cells) is linked to how quickly resistance mutations develop in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. Researchers analyzed blood…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Mold infection risk in kids with leukemia: a 14-year review
Knowledge-focused CompletedThis study looked back at 621 children in Denmark who had chemotherapy for acute leukemia between 2008 and 2022. The goal was to find out how many got serious mold infections and what factors made it more likely. The results will help doctors better protect children during treatm…
Sponsor: University of Southern Denmark • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Exercise before CAR T-Cell therapy: a step in the right direction?
Knowledge-focused CompletedThis study looked at whether an exercise program is practical for people aged 65 and older with blood cancers like lymphoma, leukemia, or myeloma who are about to receive CAR T-cell therapy. The program included remote exercise sessions and was tested with 20 participants to see …
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
Heart risks during CAR T-Cell therapy under the microscope
Knowledge-focused CompletedThis study followed 44 adults with leukemia or lymphoma who received CAR T-cell therapy to see how their hearts were affected. Researchers used heart scans, blood tests, and quality-of-life surveys before and after treatment. The goal was to learn how often heart problems occur a…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
HIV Patients' CAR T-Cell cancer treatment under the microscope
Knowledge-focused CompletedThis study looked back at 30 people with HIV who received a special cancer treatment called CAR T-cell therapy for certain blood cancers. Researchers collected information from medical records to see what side effects occurred and how the immune system changed over time. The goal…
Sponsor: AIDS Malignancy Consortium • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Can a smartphone app ease the burden for young cancer survivors?
Knowledge-focused CompletedThis completed trial tested an interactive survivorship program for adolescent and young adult cancer survivors. The program included a mobile app, telehealth support, and printed materials to help survivors access healthcare resources, improve self-management skills, and reduce …
Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Can we predict who bounces back after a bone marrow transplant?
Knowledge-focused CompletedThis study looked at 126 people aged 60 and older who had a bone marrow transplant for blood cancers like leukemia or lymphoma. Researchers measured physical abilities, mental health, and stress levels before and after transplant to find traits that help people recover better. Th…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC